Advice
Following a full submission
epoetin zeta (Retacrit) is accepted for use within NHS Scotland for treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis and for treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.
Clinical studies in adult haemodialysis patients have demonstrated equivalence in correcting and maintaining haemoglobin levels when compared to another erythropoiesis stimulating agent (ESA). Unlike other ESAs, epoetin zeta is only licensed for administration by the intravenous route.
Download detailed advice95KB (PDF)
Medicine details
- Medicine name:
- epoetin zeta (Retacrit)
- SMC ID:
- 467/08
- Indication:
- Treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis (intravenous [iv] route only)
- Pharmaceutical company
- Hospira UK Limited
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 June 2008